Harrow Health, Inc.
HROW
Updated: 22/09/2026, 18:11:18
Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change from Imprimis Pharmaceuticals, Inc. to Harrow Health, Inc. in December 2018.
No summaries found.
- Share price
- $34.30
- Market cap
- $1.28B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Mark L. Baum
- Employees
- 373
- IPO date
- 28/09/2007
- Beta
- 0.241
- Last dividend
- $0.00
- Day range
- $33.68 – $34.41
- 52-week range
- $28.54 – $54.85
- 1-day performance
- 1.12%
- 1-year performance
- 20.18%
- Current drawdown (1Y)
- -37.47%
- CIK
- 0001360214
- CUSIP
- 415858109
- ISIN
- US4158581094
- Created
- 07/12/2025, 04:35:27
- Last update
- 22/09/2026, 18:11:18
Track Harrow Health, Inc. with an AI analyst
See which prediction-market events move HROW, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
Zacks Investment Research • STOCK • 11/06/2026, 13:51:08
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare
GlobeNewsWire • STOCK • 10/06/2026, 09:00:00
HROW Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Harrow for Potential Securities Law Violations
GlobeNewsWire • STOCK • 13/05/2026, 12:13:00
Harrow, Inc. (HROW) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 12/05/2026, 16:30:51
Harrow Q1 Earnings Call Highlights
MarketBeat • STOCK • 12/05/2026, 13:11:30
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research • STOCK • 04/05/2026, 13:00:28
Harrow: Now Is The Buy Time
Seeking Alpha • STOCK • 20/04/2026, 09:30:00
Harrow: Probably A Short-Term Market Overreaction
Seeking Alpha • STOCK • 14/04/2026, 07:33:55
Harrow Health (NASDAQ:HROW) Maintains "Buy" Rating and Showcases Growth in Ophthalmic Sector
Market Data • Market Data • 24/03/2026, 14:13:14
Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth
GlobeNewsWire • STOCK • 24/03/2026, 09:15:00
Harrow Emerging As Dominant Operator In U.S. Ophthalmic Market
Seeking Alpha • STOCK • 17/03/2026, 15:00:27
Harrow: The Post Earnings Drop Exposes The Cost Of Growth (Rating Downgrade)
Seeking Alpha • STOCK • 04/03/2026, 07:46:19